Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench

Targeted therapies are efficient in the context of oncogenic driver mutations. Epidermal growth factor receptor (EGFR)-mutant lung cancers represent a distinct subset of non-small-cell lung cancer (NSCLC) with marked sensitivity to EGFR tyrosine kinase inhibitors (TKIs). Despite the high response ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Rui, Zhao, Jing, Xia, Lexin, Li, Qin, Li, Wen, Peng, Ling, Xia, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285948/
https://www.ncbi.nlm.nih.gov/pubmed/32565926
http://dx.doi.org/10.1177/1758835920930333

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285948/
https://www.ncbi.nlm.nih.gov/pubmed/32565926
http://dx.doi.org/10.1177/1758835920930333

Ejemplares similares